Maximum Dose of Lovastatin
The maximum recommended dose of lovastatin is 80 mg per day for adults in the general population 1.
Standard Dosing Parameters
The FDA-approved dosing range for lovastatin is 10-80 mg daily, administered with meals 1. The typical starting dose is 20 mg once daily with the evening meal, though 10 mg may be appropriate for patients requiring smaller LDL-C reductions 1.
Critical Dose Restrictions Based on Drug Interactions
Important caveat: The 80 mg maximum does NOT apply to all patients. Several common cardiovascular medications require significant dose restrictions:
Severe Restrictions (Maximum 20 mg/day)
When taking danazol, diltiazem, dronedarone, or verapamil concomitantly, lovastatin must not exceed 20 mg daily and should start at 10 mg 1. These drugs inhibit CYP3A4, dramatically increasing lovastatin levels and myopathy risk.
Moderate Restriction (Maximum 40 mg/day)
When taking amiodarone, lovastatin dose must not exceed 40 mg daily 1.
Renal Impairment Restriction
In patients with severe renal insufficiency (creatinine clearance <30 mL/min), doses above 20 mg/day should be carefully considered and implemented cautiously if deemed necessary 1. This population shows approximately two-fold higher plasma concentrations of active inhibitors 1.
Special Population: Adolescents
For adolescent patients (10-17 years) with heterozygous familial hypercholesterolemia, the maximum dose is 40 mg daily, not 80 mg 1.
Clinical Context from Guidelines
The 2018 AHA/ACC cholesterol guidelines classify lovastatin 40-80 mg as high-intensity statin therapy (expected to lower LDL-C ≥50%), while lovastatin 20 mg is moderate-intensity therapy 2. However, the guidelines note that simvastatin 80 mg initiation or titration is not recommended by the FDA due to myopathy risk—a similar concern exists with lovastatin at maximum doses, particularly with interacting medications.
Common Pitfall to Avoid
Do not prescribe lovastatin 80 mg without first checking for CYP3A4 inhibitors (including grapefruit juice, which can increase lovastatin levels 15-fold) 1. The risk of myopathy and rhabdomyolysis increases substantially with elevated plasma levels of HMG-CoA reductase inhibitory activity 1.